Prescribing Levomilnacipran

Why Levomilnacipran, and Where It Fits

Levomilnacipran (Fetzima) is the newest and least-used of the SNRIs, FDA-approved for major depressive disorder in adults in July 2013. It is the purified levorotatory enantiomer of milnacipran (the drug marketed in the US as Savella for fibromyalgia), repackaged as a once-daily extended-release antidepressant. Its one genuinely distinctive feature: it is the most noradrenergic of the SNRIs, with roughly 2-fold greater potency at the norepinephrine transporter than the serotonin transporter at therapeutic doses. Every other SNRI is predominantly serotonergic even at full dose (duloxetine about 20:1 toward serotonin, venlafaxine about 120:1 toward serotonin). Levomilnacipran flips that ratio.

That inversion is the whole marketing story, and it is worth being honest about how little clinical mileage it buys. The seductive theory is a "norepinephrine-deficit depression" phenotype (the slowed-down, fatigued, apathetic, poorly-concentrating patient) who ought to respond preferentially to a noradrenergic agent. It is a plausible story. It is also a story that the drug's own post-hoc symptom-cluster analyses failed to support: levomilnacipran did not preferentially improve energy, motivation, or concentration relative to its overall antidepressant effect. It improves the same symptom domains as every other antidepressant, by about the same amount.

So the practical framing is this: levomilnacipran is a reasonable second- or third-line SNRI, not a first-line agent and not a magic bullet for the tired patient. It behaves clinically a lot like bupropion (activating, sometimes jittery, sweat-inducing, weight-neutral-ish), which makes it a defensible pick for the slowed, low-energy patient who has failed or can't tolerate SSRIs, bupropion, and the workhorse SNRIs. Two features are legitimately in its favor: a clean drug-interaction profile (it is not a meaningful CYP inhibitor and is mostly cleared by glucuronidation), and a genuinely once-daily schedule. Two features work against it: it is hard to tolerate and hard to titrate (nausea, constipation, sweating, tachycardia), and it has no demonstrated efficacy advantage over any cheaper, better-established alternative.

Part 1: Indications: Who Is It For?

FDA-Approved Use

• Major depressive disorder (MDD) in adults. That is the entire label.

Note what is not on the label. Unlike duloxetine and the parent compound milnacipran (Savella), levomilnacipran is not approved for fibromyalgia or any pain indication, and it was never pursued for one. Do not prescribe it expecting analgesia. It has no approved anxiety indication either (no GAD approval, unlike venlafaxine, desvenlafaxine, and duloxetine).

The Realistic Clinical Role

• Second- or third-line MDD. After an adequate SSRI trial fails or isn't tolerated, and typically after the more established SNRIs (venlafaxine, duloxetine) and bupropion have been considered.
• The "slowed-down and tired" phenotype. The best-articulated niche: prominent fatigue, low motivation, apathy, psychomotor slowing, poor concentration, cognitive dulling. This is the same patient many clinicians would first try bupropion in, and levomilnacipran handles a lot like bupropion. Reach for it when bupropion has failed or is contraindicated (e.g., seizure risk, eating disorder) but you still want an activating agent.
• Melancholic depression, on the general principle that noradrenergically-active agents (SNRIs, tricyclics) may edge out pure serotonergics here, though the evidence is a clinical impression, not a robust finding.

Who It's Not For

• The anxious, agitated, or activation-prone patient. Its noradrenergic push (jitteriness, tachycardia, restlessness) can worsen anxiety, the opposite of what you want.
• The cardiovascularly fragile patient (see cautions): it raises heart rate and blood pressure.
• The patient who needs a cheap generic: Fetzima is branded and expensive, and there is no direct generic substitute (generic milnacipran is a different, racemic drug for a different indication).

Part 2: Before You Start: Workup and Candidacy

Levomilnacipran requires no routine laboratory monitoring and no serum drug levels; this is not lithium. The pre-start workup is clinical and brief.

Poor Candidates

• Uncontrolled or labile hypertension; significant tachyarrhythmia or unstable cardiac disease
• Current MAOI use (or within 14 days)
• End-stage renal disease
• Chronic constipation / significant GI dysmotility (it is among the most constipating antidepressants)
• The highly anxious or activation-sensitive patient

Part 3: How to Start and Dose

Formulation

Fetzima is supplied as extended-release capsules in 20 mg, 40 mg, 80 mg, and 120 mg strengths, taken once daily, with or without food. Swallow whole: do not crush, chew, or open the capsule (it defeats the extended-release delivery). Dose at a consistent time each day; morning dosing is generally preferred because the drug is activating and can disrupt sleep if taken late.

Starting Dose and Titration

The label permits a fairly brisk titration (increments as often as every 2 days), but in real practice go slower than the label allows. This is described repeatedly as a hard drug to tolerate, and rushing the titration is the fastest way to lose the patient to nausea, constipation, or sweating before they ever reach a therapeutic dose.

1. Day 1–2
   20 mg once daily. A tolerability lead-in, not a therapeutic dose.
2. Day 3
   Increase to 40 mg once daily. This is the minimum effective/therapeutic dose.
3. Day 5 onward
   Titrate in 40 mg increments at intervals of ≥2 days, as tolerated, through the therapeutic range: 40 → 80 → 120 mg once daily.

Approved therapeutic range: 40–120 mg once daily. Maximum: 120 mg/day.

Renal Dose Caps: Don't Miss These

Because clearance is renal, the maximum dose is reduced in renal impairment (see Special Populations for detail):

• Moderate renal impairment (eGFR/CrCl 30–59): maximum 80 mg/day
• Severe renal impairment (eGFR/CrCl 15–29): maximum 40 mg/day
• End-stage renal disease: not recommended

No dose adjustment is needed for mild renal impairment or for hepatic impairment (glucuronidation is relatively preserved).

Onset and Duration

Efficacy was established in 8-week placebo-controlled trials. As with all antidepressants, expect 4–8 weeks at a therapeutic dose (≥40 mg) before judging response, and give benefit time to accrue. Don't call it a failure at a subtherapeutic dose or after two weeks of nausea.

Part 4: Monitoring

There are no blood levels and no mandatory labs. The monitoring that matters is clinical and autonomic:

Part 5: Side Effects and How to Manage Them

The governing theme: levomilnacipran's side effects are dominated by its noradrenergic pharmacology: sweating, constipation, tachycardia, and activation. Many patients develop tolerance to the early GI and activation effects over the first several weeks; counsel this up front so they don't quit at week two.

Gastrointestinal

Nausea is the most common adverse effect and a frequent early dealbreaker.

• Among antidepressants it ranks near the top for nausea (behind duloxetine and vortioxetine).
• Management: take with food; slow the titration; reassure that tolerance usually develops over 2–4 weeks. A short-course antiemetic (e.g., ondansetron) can bridge the initiation period if needed.

Constipation is the other GI signature and, unlike nausea, is noradrenergically mediated and dose-dependent: it doesn't reliably fade and can persist at higher doses.

• Management: proactive bowel regimen from the start in constipation-prone patients: hydration, dietary fiber, exercise, and an osmotic laxative (e.g., polyethylene glycol) as needed. If constipation is refractory, cut the dose; it tracks with dose.

Vomiting occurs but is less common than nausea.

Cardiovascular and Autonomic

This is the system to watch. Noradrenergic tone produces heart rate increase, blood pressure elevation, and prominent sweating.

• Heart rate increase / tachycardia and palpitations, dose-related; can be clinically meaningful in patients with cardiac disease.
• Blood pressure elevation, a class effect of SNRIs; check BP at baseline and after titration.
• Hyperhidrosis (excessive sweating), prominent, noradrenergically driven, and much like bupropion's sweating. It's a common nuisance and occasional reason to stop.

Management: for troublesome sweating, dose reduction is the main lever; some clinicians add a low-dose alpha-blocker (e.g., terazosin) or an anticholinergic for refractory hyperhidrosis, but the simplest move is often to reduce the dose or switch.

Activation / Behavioral

Jitteriness, shakiness, restlessness, and insomnia, again, a lot like bupropion. Some patients find the initial stimulation intolerable, particularly if they are anxious.

• Management: dose in the morning; start low and titrate slowly; reassure that activation typically settles by around week 6. If it persists or the patient is anxious-agitated, this is likely the wrong drug for them.

Sexual Dysfunction

Present, as with all serotonergically-active antidepressants, and do not expect an advantage over venlafaxine or duloxetine.

• Package-insert rates (spontaneous, therefore underestimates): erectile dysfunction about 6% (vs about 1% placebo), ejaculatory dysfunction about 5% (vs <1% placebo), female sexual dysfunction reported <2% (almost certainly higher when asked directly).
• Management: the usual toolkit: wait for possible accommodation, dose reduction, a PDE5 inhibitor for ED, or switch to a genuinely SD-sparing agent (bupropion, mirtazapine). Its noradrenergic profile does not spare sexual function the way its marketing might imply.

Other / Class Effects

• Hyponatremia / SIADH: uncommon; risk concentrated in the elderly, volume-depleted, and diuretic-treated. Check sodium if a patient develops confusion, headache, or unsteadiness.
• Bleeding risk: like other serotonergic agents, mild antiplatelet effect, additive with NSAIDs/anticoagulants; counsel and monitor.
• Urinary hesitancy/retention: the noradrenergic (alpha-adrenergic) effect on the bladder outlet can, uncommonly, cause hesitancy, more of a concern in men with prostatic hypertrophy.

Part 6: Overdose, Toxicity, and Boxed Warning

Overdose

There is limited human overdose experience specific to levomilnacipran. Expect an exaggeration of its pharmacology and the general SNRI overdose picture: nausea/vomiting, tachycardia, hypertension, diaphoresis, agitation, tremor, and, as with any serotonergic agent, potential for serotonin syndrome (hyperthermia, autonomic instability, clonus, rigidity, altered mental status), and, less commonly, seizures. Overdose management is supportive (airway, cardiac monitoring, IV fluids, symptomatic control of BP/HR and agitation); there is no specific antidote. Consult poison control. As with all SNRIs, overdose risk is amplified by co-ingestants (alcohol, other CNS/serotonergic drugs).

Serotonin Syndrome

A labeled risk whenever combined with other serotonergic agents (see Interactions). Absolutely contraindicated with MAOIs.

Part 7: Drug Interactions

This is one of levomilnacipran's real strengths.

The Good News: Minimal CYP Liability

• Cleared largely by glucuronidation with only modest oxidative (CYP3A4) contribution; it does not meaningfully inhibit CYP2D6, CYP2C19, or CYP3A4.
• This puts it, alongside desvenlafaxine, among the cleanest SNRIs for polypharmacy, a genuine advantage over duloxetine (a strong 2D6 inhibitor with hepatotoxicity concerns), venlafaxine (2D6/3A4 substrate), vortioxetine (2D6 substrate), and vilazodone (3A4 substrate).
• Practical payoff: it plays well with tricyclics, 2D6-dependent antipsychotics (aripiprazole, risperidone, brexpiprazole), stimulants, and other 2D6 substrates without the level-raising interactions those drugs suffer with more inhibitory antidepressants.

One caveat: because CYP3A4 contributes to its metabolism, strong 3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) can raise its levels: the label caps the dose at 80 mg/day with a strong 3A4 inhibitor. Strong 3A4 inducers (and, per the source notes, tobacco smoke) may lower levels; on smoking cessation, expect the induction to reverse over roughly a week.

The Interactions That Still Matter (Pharmacodynamic, Not CYP)

• MAOIs, absolute contraindication. No concurrent use; allow 14 days between stopping an MAOI and starting levomilnacipran, and 14 days after stopping levomilnacipran before an MAOI. Includes linezolid and IV methylene blue.
• Other serotonergic agents (SSRIs, other SNRIs, triptans, tramadol, dextromethorphan, St. John's wort): additive serotonin syndrome risk. (Note: the old triptan-SNRI warning has been substantially walked back, large studies show the combination is generally safe, but remain alert.)
• Sympathomimetics / noradrenergic drugs (stimulants, pseudoephedrine and other decongestants, atomoxetine): additive blood pressure and heart rate elevation, the most clinically relevant pharmacodynamic interaction given this drug's autonomic profile. Monitor vitals.
• NSAIDs, aspirin, anticoagulants/antiplatelets: increased bleeding risk from additive platelet effects.

Part 8: Special Populations

Renal Impairment: The Population That Changes Your Dosing

This is the single most important special-population point, because clearance is renal:

• Mild impairment: no adjustment.
• Moderate impairment (eGFR/CrCl 30–59): maximum 80 mg/day.
• Severe impairment (eGFR/CrCl 15–29): maximum 40 mg/day.
• End-stage renal disease: not recommended.

Hepatic Impairment

No dose adjustment is required for mild, moderate, or severe hepatic impairment, a consequence of the primarily glucuronidation-based clearance. This is a modest advantage over duloxetine (avoid in hepatic disease) and venlafaxine (dose reduction needed).

Elderly

• Start low, go slow. No mandatory age-based dose reduction, but the elderly are more vulnerable to the drug's autonomic effects (tachycardia, BP), to hyponatremia/SIADH, and often have reduced renal function that pulls the effective ceiling down. Check renal function and let it set your maximum.
• The clean CYP profile is a real asset in the polypharmacy-heavy older patient: less interaction risk than duloxetine or venlafaxine.

Pregnancy

• Levomilnacipran-specific pregnancy data are sparse. Reason from the SNRI/antidepressant class: large datasets do not show an increased risk of major congenital malformations or autism with SSRIs/SNRIs as a group.
• Third-trimester exposure carries a risk of poor neonatal adaptation (jitteriness, irritability, feeding/tone changes, respiratory signs), usually self-limited, and a small, rare PPHN signal described mainly for SSRIs.
• Approach: individualize; weigh the real risks of untreated maternal depression; prefer an agent with more reproductive-safety data (and one the patient has responded to before) over a newer, thinly-studied drug like this one unless there is a specific reason to use it.

Lactation

Minimal specific data. For breastfeeding, better-studied antidepressants (sertraline foremost; among SNRIs, venlafaxine/duloxetine have more data) are generally preferred. If used, monitor the infant for irritability, poor feeding, and sedation.

Children and Adolescents

Not approved and not established in pediatric patients. The class boxed warning for increased suicidality in patients under 25 applies. Use SSRIs with pediatric evidence (fluoxetine, escitalopram) first.

Part 9: Discontinuation and Taper

Levomilnacipran has a relatively short half-life (about 12 hours), which places it squarely in the high-withdrawal-risk category alongside the other short-half-life SNRIs (venlafaxine, duloxetine, desvenlafaxine) and paroxetine. Abrupt discontinuation can produce a classic SNRI discontinuation syndrome: dizziness/lightheadedness, vertigo, nausea, brain zaps, insomnia, irritability, tearfulness, and flu-like malaise.

How to Stop

Part 10: Levomilnacipran vs the Alternatives

Head-to-head, the honest verdict is no demonstrated efficacy advantage over anything. The distinctions are about pharmacology, tolerability, and interaction profile, not outcomes.

The efficacy baseline (be sober about it): In a meta-analysis of the pivotal 8-week, placebo-controlled, company-funded trials, levomilnacipran gave response about 46% vs 36% placebo and remission about 28% vs 22% placebo, a modest, real, but unremarkable separation from placebo, with no active comparator. On the Sheehan Disability Scale the functional advantage over placebo was small (about 2.2 points). There is no head-to-head trial showing it beats any other antidepressant.

• vs SSRIs: No efficacy advantage; more constipating, more sweating, more activation. SSRIs are first-line, generic, and better tolerated for most. Choose levomilnacipran only for a specific noradrenergic/activation rationale after SSRIs.
• vs Venlafaxine: Levomilnacipran is far more noradrenergic; venlafaxine is predominantly serotonergic (and has a reliable dose-response curve and a proven efficacy edge over SSRIs). Both have short half-lives and meaningful withdrawal. Levomilnacipran wins on fewer CYP interactions; venlafaxine wins on cost and evidence base.
• vs Duloxetine: Levomilnacipran is more noradrenergic and much cleaner on drug interactions and the liver (duloxetine is a strong 2D6 inhibitor with a hepatotoxicity signal and urinary-retention risk). But duloxetine treats pain and anxiety with real evidence; levomilnacipran does neither on-label. No efficacy advantage either way.
• vs Desvenlafaxine: The closest comparator on interaction profile (both largely glucuronidated, both clean for polypharmacy). Desvenlafaxine is serotonergic and needs no titration; levomilnacipran is noradrenergic and must be titrated carefully. Similar (unremarkable) efficacy.
• vs Bupropion: The most useful clinical comparison, because they handle alike: both activating, both good candidates for the fatigued, slowed patient, both cause jitteriness/sweating, both relatively weight- and sex-sparing (bupropion more so). Bupropion is generic, cheap, has no serotonin-syndrome/serotonergic-withdrawal baggage, and is a true SD-sparing agent, so bupropion usually comes first. Levomilnacipran is the fallback when bupropion fails or is contraindicated (seizure disorder, eating disorder, bupropion intolerance) but you still want an activating drug, with the bonus of a serotonergic component bupropion lacks.

So why is it barely used? No efficacy edge, branded pricing with no clean generic substitute, a difficult tolerability/titration profile, and a signature "noradrenergic selectivity" whose promised clinical benefit didn't materialize in the data. Its legitimate niche is narrow: the interaction-constrained, activation-appropriate patient who has run through the cheaper options.

Mechanism: The Short Version

Levomilnacipran is the levorotatory enantiomer of milnacipran, a potent dual reuptake inhibitor of serotonin and norepinephrine. Its defining pharmacologic feature is preferential norepinephrine transporter inhibition, roughly 2-fold greater potency at NET than SERT at therapeutic doses, making it the most noradrenergically-weighted SNRI (the noradrenergic ranking runs levomilnacipran > duloxetine > venlafaxine/desvenlafaxine; it's been likened to protriptyline among the tricyclics). Crucially, this NE selectivity narrows at higher doses as serotonergic occupancy rises, so the drug's distinctiveness is greatest in its lower-to-mid dose range.

The intended clinical corollary, that greater noradrenergic tone should preferentially lift energy, drive, and concentration ("norepinephrine-deficit depression"), is mechanistically tidy but clinically unconfirmed: post-hoc analyses found no preferential benefit on those symptom domains. The lesson generalizes: as STAR*D taught us, an antidepressant's reuptake-selectivity profile does a poor job of predicting which patient responds. Levomilnacipran's noradrenergic signature reliably predicts its side-effect profile (sweating, constipation, tachycardia, activation) far better than it predicts its therapeutic profile.

Pharmacokinetically: once-daily extended-release delivery, half-life about 12 hours (hence the withdrawal liability), cleared mainly by glucuronidation with modest CYP3A4 involvement, and renally eliminated (hence the renal dose caps).

The Bedside Cheat Sheet